Zobrazeno 1 - 1
of 1
pro vyhledávání: '"Kiat Hon Lim, MBBS"'
A Randomized Phase 2 Trial of Nivolumab Versus Nivolumab-Ipilimumab Combination in EGFR-Mutant NSCLC
Autor:
Gillianne G.Y. Lai, MBBS, Jia Chi Yeo, PhD, Amit Jain, MBBS, PhD, Siqin Zhou, MSc, Mengyuan Pang, MSc, Jacob J.S. Alvarez, BSc, Ngak Leng Sim, BCS, Aaron C. Tan, MBBS, FRACP, PhD, Lisda Suteja, BSc, Tze Wei Lim, BSc, Yu Amanda Guo, PhD, Meixin Shen, PhD, Stephanie P.L. Saw, MBBS, Neha Rohatgi, BSc, Joe P.S. Yeong, MBBS, PhD, Angela Takano, MBBS, Kiat Hon Lim, MBBS, Apoorva Gogna, MBBS, Chow Wei Too, MBBS, Kun Da Zhuang, MBBS, Wan Ling Tan, MBBS, Ravindran Kanesvaran, MBBS, Quan Sing Ng, MBBS, Mei Kim Ang, MBBS, Tanujaa Rajasekaran, MBBS, Lanying Wang, MBBS, Chee Keong Toh, MBBS, Wan-Teck Lim, MBBS, Wai Leong Tam, PhD, Sze Huey Tan, PhD, Anders M.J. Skanderup, PhD, Eng-Huat Tan, MBBS, Daniel S.W. Tan, BSc, MBBS, MRCP, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 12, Pp 100416- (2022)
Introduction: Although immune checkpoint inhibitors (ICIs) have dramatically improved outcomes for nononcogene-addicted NSCLC, monotherapy with programmed cell death protein-1 (PD1) inhibition has been associated with low efficacy in the EGFR-mutant
Externí odkaz:
https://doaj.org/article/7d3ef7d52e0641cbadf717aeaf522b4b
